A major study reveals how chemotherapy reshapes the environment around pancreatic tumors, helping explain why some patients do not respond to treatment. Using advanced single-cell and spatial analysis, researchers identified a “chemoresistant niche” where aggressive tumor cells, immune-suppressing macrophages, and exhausted T cells work together to protect the cancer.
The study highlights CD276 (also known as B7-H3) as a key driver of this resistance. This molecule pushes tumor cells into a more aggressive, treatment-resistant state while also weakening the immune system by exhausting T cells and reprogramming macrophages to support tumor growth. Patients who did not respond to chemotherapy had significantly higher levels of CD276 and more of these resistant cell types.
In preclinical models, blocking CD276 alongside standard chemotherapy significantly reduced tumor growth and improved survival. The treatment also reversed tumor resistance and restored immune activity. These findings suggest that targeting CD276 could become a powerful new strategy to enhance chemotherapy and overcome resistance in pancreatic cancer.